HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function
A legfontosabb adatok
- Ki végzi
- VA Office of Research and Development
- Hol
- Portland (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Befejeződött
- Résztvevők
- 63 fő vett részt
- Kezdés
- 2019. máj. 16.
- Befejezés
- 2023. dec. 29.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A vizsgált kezelések
- Neuropsychological assessment
- Neuroimaging
- A regiszteradat frissítve
- 2025. március 27.
Ki vehet részt
- Életkor
- 21 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 8 feltétel megnézéseKevesebb
Ki vehet részt
- Adult Veteran (>21 years)
- Able to provide informed consent
Ki nem vehet részt
- Contraindications to MRI (such as surgical aneurysm clips, pacemaker, prosthetic heart valve, neuro-stimulator, implanted pumps, cochlear implants, metal rods, plates or screws, previous surgery, hearing aids, history of welding, metal shrapnel)
- Current substance use disorder other than alcohol (except nicotine or caffeine)
- Medical conditions likely to impact immunological function or central nervous system function (such as HIV, cancer, lupus, stroke, neurodegenerative disease, hepatic encephalopathy, multiple sclerosis, or a traumatic brain injury)
- Past or present schizophrenia, schizoaffective disorder, or current psychosis or mania
- Visible intoxication or impaired capacity to understand study risks and benefits or otherwise provide informed consent
- Visual or auditory impairments that would prevent valid neuropsychiatric testing
Helyszínek itt: Egyesült Államok
- VA Portland Health Care System, Portland, ORPortland, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and after direct-acting antiviral (DAA) therapy [a new treatment for chronic infection with the hepatitis C virus (HCV)]. Demographically-matched comparison groups of Veterans without HCV (HCV-, with and without AUD) will similarly be evaluated to determine the relative contribution of HCV and an HCV "cure" to outcomes putatively affected by alcohol abuse.
A teljes eredeti leírásKevesebb
Two specific aims are proposed.
Aim 1: Determine the impact of DAA therapy and a sustained viral response on central nervous system (CNS) function.
Aim 2: Evaluate the effects of AUD and unhealthy alcohol drinking on DAA therapy outcomes and CNS function.
The information learned will address a critical gap in knowledge concerning the effects of alcohol use on DAA therapy outcomes and will help inform treatment guidelines that could be translated to clinical practice, such as targeted interventions to treat AUD in conjunction with HCV infection and follow-up strategies for patients who successfully complete DAA therapy but then need care for other potential CNS-related outcomes.
A vizsgálat 4 csoportja
- AUD+/HCV+
* With current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV
Kezelés: Neuropsychological assessment és Neuroimaging
- AUD-/HCV+
* Without current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV
Kezelés: Neuropsychological assessment és Neuroimaging
- AUD+/HCV-
-With Alcohol Use Disorder and without HCV
Kezelés: Neuropsychological assessment és Neuroimaging
- AUD-/HCV-
-Without Alcohol Use Disorder and without HCV
Kezelés: Neuropsychological assessment és Neuroimaging
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2025. március 27.